KR927003624A - 화합물 - Google Patents
화합물 Download PDFInfo
- Publication number
- KR927003624A KR927003624A KR1019920700412A KR920700412A KR927003624A KR 927003624 A KR927003624 A KR 927003624A KR 1019920700412 A KR1019920700412 A KR 1019920700412A KR 920700412 A KR920700412 A KR 920700412A KR 927003624 A KR927003624 A KR 927003624A
- Authority
- KR
- South Korea
- Prior art keywords
- hydroxyamino
- compound
- amide
- phenylalanine
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
Abstract
내용 없음
Description
화합물
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (17)
- 다음 일반식(I)의 화합물 또는 이의 염과 또는 N-산화물과 또는 (여기서 화합물은 티오-화합물)이의 술폭시드나 술폰상기식에서, R1은 수소원자 또는 C1-C6알킬, C1-C6알켄일, 페닐, 페닐(C1-C6)알킬, C1-C6알킬티오메틸, 페닐티오메틸, 치환 페닐티오메틸, 페닐(C1-C6)알킬티오메틸 또는 헤테로시클로일티오메틸기를 나타내거나; 또는 R1은 -S-Rx를 나타낸다.(여기서 Rx는 다음 구조식의 기를 나타낸다;R2는 수소원자 또는 C1-C6알킬, C1-C6알켄일, 페닐(C1-C6)알킬. 시클로알킬 (C1-C6)알킬, 또는 시클로알켄일(C1-C6)알킬을 나타내며; R3는 아미노산 측쇄 또는 C1-C6알킬, 벤질, (C1-C6)-알콕시벤질, 벤질옥시(C1-C6)알킬 또는 벤질옥시벤질기를 나타내며, R4는 수소원자 또는 메틸기를 나타내며; R5는 (CH2)nA기를나타내며; 또한 R4와 R5는기를 나타내며, Q는 CH2또는 CO를나타내며; m은1-3의 정수이고, n은 1-6의 정수이고; A는 히드록시, (C1-C6)알콕시, (C2-C7)아실옥시, (C1-C6)알킬티오, 페닐티오, (C2-C7)아실아미노 또는 N-피롤리돈기를 나타낸다.
- 제1항에 있어서, 치환기 R3에 인접한 키럴 중심이 S입체화학구조를 가짐을 특징으로 하는 화합물.
- 제1항 또는 제2항에 있어서, R1이 수소원자 또는 C1-C4알킬, 페닐티오 메틸 또는 헤테로시클일티오메틸기임을 특징으로 하는 화합물.
- 제1항, 제2항 또는 제3항에 있어서, R2가 C3-C6알킬기를 나타냄읕 특징으로하는 화합물.
- 제1항 내지 제4항중 어느 한 항에 있어서, R3가 벤질, 4-(C1-C6)알콕시페닐메틸 또는 벤질옥시 벤질기를 나타냄을 특징으로 하는 화합물.
- 제1항 내지 제5항중 어느 한 항에 있어서, R4가 수소원자를 나타내거나 또는 R4가 R5가 함께기를 나타냄을 특징으로 하는 화합물.
- 제1항 내지 제6항중 어느 한 항에 있어서, n가 1,2 또는 3의 값을 가짐을 특징으로하는 화합물
- 제1항 내지 제7항중 어느 한 항에 있어서, R5가 피롤리돈, 히드록시, 메톡시 또는 티오에틸기를 나타냄을 특징으로 화합물.
- [4-(N-히드록시아미노)-2R-이소부틸석신일]-L-페닐알라닌-N-(2-히드록시에틸)-아미드; [4-(N-히드록시아미노)-2R-이소부틸석신일]-L-페닐알라닌일; [4-(N-히드록시아미노)-2R-이소부틸석신일]-L-페닐알라닌-N-(2-히드록시에틸)-N-메틸아미드; [4-(N-히드록시아미노)-2R-이소부틸석신일]-L-페닐알라닌일-D-프로린올; [4-(N-히드록시아미노)-2R-이소부틸석신일]-L-페닐알라닌-L-프로린올; [4-(N-히드록시아미노)-2R-이소부틸석신일]-L-페닐알라닌-N-(5-N-메틸-펜릴카르복스아미드)아미드; [4-(N-히드록시아미노)-2R-이소부틸석신일]-L-페닐알라닌일-N-(2-에틸티오에틸)아미드; [4-(N-히드록시아미노)-2R-이소부틸석신일]-L-페닐알라닌일-N-(2-메톡시에틸)아미드; [4-(N-히드록시아미노)-2R-이소부틸석신일]-L-페닐알라닌-N-(2-아세틸에틸)아미드; [4-(N-히드록시아미노)-2R-이소부틸석신일]-L-페닐알라닌-N-(3-2-피롤리돈)프로필)아미드; [4-(N-히드록시아미노)-2R-이소부틸석신일]-L-페닐알라닌-N-(3-2-피롤리돈)프로필)아미드; [4-(N-히드록시아미노)-2R-이소부틸석신일]-L-페닐알라닌-N-(2-아세톡시에틸)아미드; [4-(N-히드록시아미노)-2R-이소부틸-3S-메틸석신일]-L-페닐알라닌-N-(3-(2-피롤리돈)프로필)아미드; [4-(N-히드록시아미노)-2R-이소부틸-3S-메틸석신일]-L-페닐알라닌-N-메틸-N-(2-히드록시에틸)아미드; [4-(N-히드록시아미노)-2R-이소부틸-3S-메틸석신일]-L-페닐알라닌-N-메틸-N-(2-히드록시에틸)아미드; [4-(N-히드록시아미노)-2R-이소부틸-3S-메틸석신일]-L-페닐알라닌일-D-프로리논; 또는 [4-(N-히드록시아미노)-2R-이소부틸-3S-메틸석신일]-L-페닐알라닌-N-(3-(2-피롤리돈)프로필)아미드 나트륨 염; 또는 이의 유리염기, 유산이나 염.
- [4-(N-히드록시아미노)-2R-이소부틸-3S-메틸석신]-L-페닐알라닌-N-(3-(2-피롤리돈)프로필)아미드이나 [4-(N-히드록시아미노)-2R-이소부틸-3S-메틸석신일]-L-페닐알라닌-N-(3-(2-피롤리돈)프로필)아미드, 또는 이의 염.
- [4-(N-히드록시아미노)-2R-이소부틸-3S-메틸석신일]-L-페닐알라닌일-N-(3-(2-피롤리돈)프로필)아미드 또는 이의 염.
- 제1항 내지 제11항중 어느 한 항에 있어서, 인체 또는 동물용 의약품으로 사용함을 특징으로 하는 화합물.
- 조직 퇴화를 포함한 질병의 치료와 또는 성처치유의 촉진에 사용하기 위하여 제제를 제조하여서하는 제1항 내지 제11항중 어느 한 항에 따른 화합물의 용도.
- 제1항 내지 제11항중 어느 한 항에 따른 화합물과 약학적 과 또는 수의학적으로 수용할 수 있는 담체로 이루어짐을 특징으로하는 약학적 또는 수의학적 제제.
- (a)다음 일반식(III)의 화합물을 탈보호하고,(상기식에서 R1,R2,R3,R4와 R5는 상기 일반식(I)에서 정의한 바와 같고 Z는 보호기릍 나타낸다)또는 (b)다음 일반식(I)의 화합물을,(상기식에서 R1,R2,R3,R4와 R5는 일반식(I)에서 정의한 바와 같고, 단지 R1은 수소원자를 나타낸다)히드록실아민 또는 이의 염과 반응시키고; (c)단계 a)또는 단계 b)후에 일반식(I)의 화합물을 일반식(I)의 다른 화합물로 임의로 변환시킴을 특징으로 하는 제1항에 정의된 일반식(I)로 표시되는 화합물의 제조방법.
- 다음 일반식(III)의 화합물:상기식에서, R1,R2,R3,R4와 R5는 일반식(I)에서 정의한 바와 같고, Z는 보호기를 나타낸다.
- 다음 일반식(IV)의 화합물상기식에서, R1,R2,R3,R4와 R5는 일반식(I)에서 정의한 바와 같고, 단지 R1은 수소원자를 나타낸다.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898919251A GB8919251D0 (en) | 1989-08-24 | 1989-08-24 | Compounds |
GB8919251.2 | 1989-08-24 | ||
PCT/GB1990/001117 WO1991002716A2 (en) | 1989-08-24 | 1990-07-20 | Hydroxamic acid based collagenase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
KR927003624A true KR927003624A (ko) | 1992-12-18 |
Family
ID=10662057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920700412A KR927003624A (ko) | 1989-08-24 | 1990-07-20 | 화합물 |
Country Status (16)
Country | Link |
---|---|
US (2) | US5453438A (ko) |
EP (1) | EP0489032B1 (ko) |
JP (1) | JP2871849B2 (ko) |
KR (1) | KR927003624A (ko) |
AT (1) | ATE111443T1 (ko) |
AU (1) | AU639706B2 (ko) |
CA (1) | CA2064786A1 (ko) |
DE (1) | DE69012575T2 (ko) |
DK (1) | DK0489032T3 (ko) |
ES (1) | ES2063975T3 (ko) |
FI (1) | FI920771A0 (ko) |
GB (1) | GB8919251D0 (ko) |
NO (1) | NO920702L (ko) |
NZ (1) | NZ235050A (ko) |
TW (1) | TW202456B (ko) |
WO (1) | WO1991002716A2 (ko) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8827308D0 (en) * | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5892112A (en) * | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
US5268384A (en) * | 1990-11-21 | 1993-12-07 | Galardy Richard E | Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors |
EP0520573A1 (en) * | 1991-06-27 | 1992-12-30 | Glaxo Inc. | Cyclic imide derivatives |
AU3899193A (en) * | 1992-04-07 | 1993-11-08 | British Bio-Technology Limited | Hydroxamic acid based collagenase and cytokine inhibitors |
GB9211706D0 (en) * | 1992-06-03 | 1992-07-15 | Celltech Ltd | Peptidyl derivatives |
GB9211707D0 (en) * | 1992-06-03 | 1992-07-15 | Celltech Ltd | Peptidyl derivatives |
US5326760A (en) * | 1992-06-29 | 1994-07-05 | Glaxo, Inc. | Aminobutanoic acid compounds having metalloprotease inhibiting properties |
GB9215665D0 (en) * | 1992-07-23 | 1992-09-09 | British Bio Technology | Compounds |
GB9223904D0 (en) * | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
US5646167A (en) * | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
CA2158352A1 (en) * | 1993-03-16 | 1994-09-29 | Michael John Crimmin | Hydroxamic acid derivatives as metalloproteinase inhibitors |
GB9308695D0 (en) * | 1993-04-27 | 1993-06-09 | Celltech Ltd | Peptidyl derivatives |
ATE182137T1 (de) * | 1993-04-27 | 1999-07-15 | Celltech Therapeutics Ltd | Peptidylderivate als inhibitoren von metalloproteinase |
ES2075797B1 (es) * | 1993-08-18 | 1996-05-16 | British Bio Technology | Derivados de acidos hidroxamicos terapeuticamente activos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina. |
ES2075798B1 (es) * | 1993-08-18 | 1996-03-01 | British Bio Technology | Derivados de aminoacidos naturales como inhibidores de metaloproteinasas, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina. |
US6037472A (en) | 1993-11-04 | 2000-03-14 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
ES2144819T3 (es) * | 1994-01-20 | 2000-06-16 | British Biotech Pharm | L-terc-leucina-2-piridilamida. |
GB9501737D0 (en) * | 1994-04-25 | 1995-03-22 | Hoffmann La Roche | Hydroxamic acid derivatives |
US5831004A (en) * | 1994-10-27 | 1998-11-03 | Affymax Technologies N.V. | Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use |
US5840698A (en) * | 1994-10-27 | 1998-11-24 | Affymax Technologies N.V. | Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use |
GB9423914D0 (en) * | 1994-11-26 | 1995-01-11 | British Biotech Pharm | Polyether derivatives as metalloproteinase inhibitors |
US5639746A (en) * | 1994-12-29 | 1997-06-17 | The Procter & Gamble Company | Hydroxamic acid-containing inhibitors of matrix metalloproteases |
US5919940A (en) * | 1995-01-20 | 1999-07-06 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
US5917090A (en) * | 1995-06-30 | 1999-06-29 | British Biotech Pharmaceuticals Ltd. | Matrix metalloproteinase inhibitors |
AU711804B2 (en) | 1995-11-23 | 1999-10-21 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
CA2263932A1 (en) * | 1996-08-28 | 1998-03-05 | Yetunde Olabisi Taiwo | 1,4-heterocyclic metalloprotease inhibitors |
JP3539736B2 (ja) * | 1996-08-28 | 2004-07-07 | ザ プロクター アンド ギャンブル カンパニー | 基質メタロプロテアーゼインヒビターとしてのホスフィン酸アミド |
CZ62899A3 (cs) * | 1996-08-28 | 1999-07-14 | The Procter & Gamble Company | 1,3-Diheterocyklické metaloproteázové inhibitory |
PT927183E (pt) * | 1996-08-28 | 2004-12-31 | Procter & Gamble | Inibidores espirociclicos de metaloproteases |
AU734834B2 (en) * | 1996-08-28 | 2001-06-21 | Procter & Gamble Company, The | Heterocyclic metalloprotease inhibitors |
US6462023B1 (en) | 1996-09-10 | 2002-10-08 | British Biotech Pharmaceuticals, Ltd. | Cytostatic agents |
BR9712019A (pt) * | 1996-09-10 | 1999-08-24 | British Biotech Pharm | Derivados de cidos hirox-mico citoest ticos |
US5840974A (en) * | 1996-12-04 | 1998-11-24 | Britisch Biotech Pharmaceuticals, Ltd. | Metalloproteinase inhibitors |
US5952320A (en) * | 1997-01-07 | 1999-09-14 | Abbott Laboratories | Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion |
US5985911A (en) * | 1997-01-07 | 1999-11-16 | Abbott Laboratories | C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion |
NZ503945A (en) | 1997-07-31 | 2002-11-26 | Procter & Gamble | Metalloprotease-inhibiting amide derivatives |
GB9810464D0 (en) * | 1998-05-16 | 1998-07-15 | British Biotech Pharm | Hydroxamic acid derivatives |
US6288261B1 (en) | 1998-12-18 | 2001-09-11 | Abbott Laboratories | Inhibitors of matrix metalloproteinases |
NZ513831A (en) | 1999-03-03 | 2001-09-28 | Procter & Gamble | Alkenyl- and alkynyl-containing metalloprotease inhibitors |
NZ517239A (en) | 1999-08-10 | 2004-09-24 | British Biotech Pharm | Antibacterial agents |
GB9929527D0 (en) * | 1999-12-14 | 2000-02-09 | Smithkline Beecham Plc | Novel compounds |
US6797820B2 (en) * | 1999-12-17 | 2004-09-28 | Vicuron Pharmaceuticals Inc. | Succinate compounds, compositions and methods of use and preparation |
AR036053A1 (es) | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
DK1406893T3 (da) | 2001-06-15 | 2007-08-06 | Vicuron Pharm Inc | Bicykliske pyrrolidinforbindelser |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4105789A (en) * | 1976-05-10 | 1978-08-08 | E. R. Squibb & Sons, Inc. | Carboxyalkylacylamino acids |
IL58849A (en) * | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
US4499079A (en) * | 1982-11-18 | 1985-02-12 | E. R. Squibb & Sons, Inc. | Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides |
US4496540A (en) * | 1982-12-30 | 1985-01-29 | Biomeasure, Inc. | Therapeutic compounds |
JPS6115840A (ja) * | 1984-07-03 | 1986-01-23 | Microbial Chem Res Found | 免疫賦活剤 |
US4743587A (en) * | 1985-09-10 | 1988-05-10 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
US4599361A (en) * | 1985-09-10 | 1986-07-08 | G. D. Searle & Co. | Hydroxamic acid based collagenase inhibitors |
DK77487A (da) * | 1986-03-11 | 1987-09-12 | Hoffmann La Roche | Hydroxylaminderivater |
FR2609289B1 (fr) * | 1987-01-06 | 1991-03-29 | Bellon Labor Sa Roger | Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes |
-
1989
- 1989-08-24 GB GB898919251A patent/GB8919251D0/en active Pending
-
1990
- 1990-07-20 AU AU60454/90A patent/AU639706B2/en not_active Ceased
- 1990-07-20 WO PCT/GB1990/001117 patent/WO1991002716A2/en active IP Right Grant
- 1990-07-20 EP EP90911398A patent/EP0489032B1/en not_active Expired - Lifetime
- 1990-07-20 CA CA002064786A patent/CA2064786A1/en not_active Abandoned
- 1990-07-20 AT AT90911398T patent/ATE111443T1/de not_active IP Right Cessation
- 1990-07-20 ES ES90911398T patent/ES2063975T3/es not_active Expired - Lifetime
- 1990-07-20 DE DE69012575T patent/DE69012575T2/de not_active Expired - Fee Related
- 1990-07-20 US US07/820,664 patent/US5453438A/en not_active Expired - Fee Related
- 1990-07-20 JP JP2510523A patent/JP2871849B2/ja not_active Expired - Fee Related
- 1990-07-20 KR KR1019920700412A patent/KR927003624A/ko not_active Application Discontinuation
- 1990-07-20 DK DK90911398.7T patent/DK0489032T3/da active
- 1990-08-01 TW TW079106338A patent/TW202456B/zh active
- 1990-08-24 NZ NZ235050A patent/NZ235050A/en unknown
-
1992
- 1992-02-21 FI FI920771A patent/FI920771A0/fi not_active Application Discontinuation
- 1992-02-21 NO NO92920702A patent/NO920702L/no unknown
-
1995
- 1995-04-05 US US08/417,095 patent/US5910609A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US5910609A (en) | 1999-06-08 |
GB8919251D0 (en) | 1989-10-04 |
NO920702L (no) | 1992-04-23 |
NO920702D0 (no) | 1992-02-21 |
DK0489032T3 (da) | 1995-01-30 |
US5453438A (en) | 1995-09-26 |
ATE111443T1 (de) | 1994-09-15 |
CA2064786A1 (en) | 1991-02-25 |
DE69012575D1 (de) | 1994-10-20 |
AU6045490A (en) | 1991-04-03 |
TW202456B (ko) | 1993-03-21 |
DE69012575T2 (de) | 1995-03-30 |
NZ235050A (en) | 1991-12-23 |
JP2871849B2 (ja) | 1999-03-17 |
ES2063975T3 (es) | 1995-01-16 |
EP0489032B1 (en) | 1994-09-14 |
AU639706B2 (en) | 1993-08-05 |
WO1991002716A3 (en) | 1991-06-27 |
EP0489032A1 (en) | 1992-06-10 |
JPH05501864A (ja) | 1993-04-08 |
FI920771A0 (fi) | 1992-02-21 |
WO1991002716A2 (en) | 1991-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR927003624A (ko) | 화합물 | |
FI100470B (fi) | Menetelmä terapeuttisesti aktiivisten hydroksaamihappojen valmistamise ksi ja välituotteet | |
FI954351A (fi) | Hydroksaamihappojohdannaiset metalloproteinaasi-inhibiittoreina | |
ES2063334T3 (es) | Inhibidores de la colagenasa basados en el acido hidroxamico. | |
DE69208089T2 (de) | Aromatische verbindungen diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung | |
ATE279391T1 (de) | Anti-imflammtorische indolderivate | |
TR200003355T2 (tr) | Sitokinin sebep olduğu hastalıkların tedavisinde benzamid türevlerinin kullanılması | |
CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
RU2002116252A (ru) | Применение производных плеуромутилина для трансдермального лечения бактериальных заболеваний | |
KR950702522A (ko) | 약리학적으로 활성인 α-[t-아미노메틸]벤젠메탄올 유도체(PHARMACOLOGICALLY ACTIVE α-[TERTIARY-AMINOMETHYL]-BENENEMETHANOL DERIATIVES) | |
DE69530771D1 (de) | Verwendung von 2-phenyl-3-aroylbenzothiophenderivaten zur herstellung eines medikaments zur knochen- und bruchheilung | |
UA71349A (uk) | Спосіб оптимізації процесу ендогенного формування мікроциркуляторного русла |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |